|Expense Ratio (net)||1.54%|
|Last Cap Gain||0.00|
|Morningstar Risk Rating||High|
|5y Average Return||N/A|
|Average for Category||N/A|
|Inception Date||Dec 27, 2012|
BOSTON, Jan. 30, 2018 /PRNewswire/ -- The Eventide Gilead Fund (ETILX) and the Eventide Healthcare & Life Sciences Fund (ETIHX) were both named as "Category Kings" by the Wall Street Journal for 2017. Both Funds are managed by Eventide Asset Management, LLC, a Boston-based registered investment adviser that designs investments for performance and a better world. Eventide CEO Robin John commented, "We are pleased with the results, yet more importantly, proud of how they were achieved.
BOSTON, Jan. 29, 2018 /PRNewswire/ -- The Eventide Healthcare & Life Sciences Fund (NASDAQ: ETIHX *), which celebrated its five-year anniversary in December, completed the five-year period ending December 31, 2017 in the top 1% of the Morningstar Health category for total return out of 121 funds. The Wall Street Journal also named the Fund a "Category King" for 2017 for ranking in the top 10 Health & Biotech funds based on total return (ranking #3 out of 99 funds).